Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Sponsor: Corbus Pharmaceuticals Inc.
Summary
The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701? What cancers can be treated effectively with CRB-701? Participants will be asked to attend clinic and be given a intravenous infusion of CRB-701. They will have blood tests, CT or MRI Scans, and other assessments to measure whether CRB-701 has an effect on tumors.
Official title: A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
348
Start Date
2024-04-01
Completion Date
2027-01-27
Last Updated
2026-01-08
Healthy Volunteers
No
Conditions
Interventions
CRB-701
Nectin-4 targeted Antibody Drug Conjugate (ADC)
Anti-PD-1
checkpoint inhibitor
Locations (41)
O'Neal Comprehensive Cancer Center at University of Alabama-Birmingham
Birmingham, Alabama, United States
City of Hope Cancer Center
Duarte, California, United States
Moores Cancer Centre at UC San Diego Health
San Diego, California, United States
Helen Diller Family Comprehensive Cancer Center - UCSF
San Francisco, California, United States
Rocky Mountain Cancer Centres
Denver, Colorado, United States
Yale Cancer Center
New Haven, Connecticut, United States
Florida Cancer Specialists
Orlando, Florida, United States
University of Chicago
Chicago, Illinois, United States
Hope and Healing Cancer Center
Hinsdale, Illinois, United States
Dana-Faber Cancer Institute
Boston, Massachusetts, United States
Nebraska Hematology Oncology
Lincoln, Nebraska, United States
Carolina BioOncology Institute
Huntersville, North Carolina, United States
Texas Oncology
Tyler, Texas, United States
Virginia Cancer Specialists
Fairfax, Virginia, United States
Fred Hutchinson Cancer Center at University of Washington
Seattle, Washington, United States
ICM-Val d'Aurelle
Montpellier, France
CHU de Poitiers
Poitiers, France
Institut de Cancerologie de l'Ouest
Saint-Herblain, France
Gustave Roussy
Villejuif, France
Careggi University Hospital
Florence, Italy
European Institute of Oncology IRCCS
Milan, Italy
Fondazione Policlinico Gemelli, IRCCS
Rome, Italy
Centro Richerche Cliniche di Verona
Verona, Italy
Institute of Oncology/ARENSIA Exploratory Medicine
Chisinau, Moldova
Aresnsia Research Clinic Bucharest
Bucharest, Romania
Aresnsia Research Clinic Cluj-Napoca
Cluj-Napoca, Romania
Centrul de Oncologie Sf. Nectarie
Iași, Romania
Centrul de Oncologie Euroclinic
Iași, Romania
Barcelona IOB Hospital Quironsalud (NEXT)
Barcelona, Spain
Vall d-Hebron Institut d'Oncologia
Barcelona, Spain
Fundacion Jimenez Diaz (START)
Madrid, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
University of Birmingham NHS Foundation Trust
Birmingham, United Kingdom
University of Cambridge NHS Foundation Trust
Cambridge, United Kingdom
Velindre Cancer Centre
Cardiff, United Kingdom
Leeds University Hospitals NHS Trust
Leeds, United Kingdom
Guy's and St Thomas' Clinical Research Facility
London, United Kingdom
Imperial Experimental Cancer Medicine Centre
London, United Kingdom
The Christie Hospital
Manchester, United Kingdom
University of Liverpool - Clatterbridge Medical Centre
Metropolitan Borough of Wirral, United Kingdom
University of Southampton
Southampton, United Kingdom